Stem Point Capital LP has filed its 13F form on November 13, 2024 for Q3 2024 where it was disclosed a total value porftolio of $334 Billion distributed in 58 stocks.
Among their holdings, we can observe that their the top five positions include companies like: Syndax Pharmaceuticals Inc with a value of $33.3B, Roivant Sciences Ltd. with a value of $32B, Merus N.V. with a value of $21B, Immunovant, Inc. with a value of $19.1B, and Arcutis Biotherapeutics, Inc. with a value of $16.5B.
Examining the 13F form we can see an decrease of $6.26B in the current position value, from $340B to 334B.
Stem Point Capital LP is based out at New York, NY
Below you can find more details about Stem Point Capital LP portfolio as well as his latest detailed transactions.